[{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAxone BioSciences Announces Notice of Allowance that Expands Scope of Key ROCK Inhibitors for Treatment of Cerebral Aneurysms","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical"},{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Neurelis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurelis Announces Acquisition Of Rights To Portfolio Of NCE Compounds","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAxone BioSciences Announces Patent Issued for Pharmaceutical Compositions of BA-210, a Rho Inhibitor for the Treatment of Spinal Cord Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by BioAxone BioSciences
BA-210 (cethrin) is a first-in-class, topically applied, biologic Rho inhibitor, developed BA-210 to inactivate Rho and has brought the compound forward to clinical testing. BA-210 has both orphan drug status and Fast Track designation from the FDA.
Neurelis intends to submit an Investigational New Drug (IND) application with the FDA on BioAxone's lead compound, BA-1049, in 2022. BioAxone's lead product, BA-1049, offers an opportunity to treat CCMs by stabilizing lesions and by preventing new lesions from emerging.
The latest notice covers the critical patent application (US 16/214,973) for the proprietary method of treatment of cerebral aneurysms with BA-1049 and other ROCK2 oral drug candidates now in development.